Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline ...

It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss ...

Novo Nordisk A/S shares fell the most since December after the drugmaker’s next-generation shot CagriSema fell short of some investors’ expectations in a clinical trial of people with diabetes.

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

I had no idea this could happen. I wouldn’t have done it,” New Jersey-based former Mounjaro user James Norris, who is now visually impaired, told The Post ...

A federal judge ended compounding pharmacies’ ability to make copies of the weight loss and diabetes drugs Zepbound and ...

Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...

Indianapolis-based Eli Lilly and Co. launched LillyDirect a little more than a year ago and has been ramping up efforts to ...

Compounders had been allowed to produce and sell hundreds of thousands of their own versions of popular anti-obesity drugs.

The makers of two popular weight-loss drugs—Wegovy and Zepbound—are cutting prices to make the medications more affordable for people without insurance. Novo Nordisk, the Danish company behind Wegovy, ...

A U.S. federal judge has restricted compounding pharmacies from making copies of Eli Lilly's weight-loss and diabetes drugs due to a lawsuit against the FDA's decision that there's no longer a ...

A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...